Tc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule
European Journal of Nuclear Medicine and Molecular Imaging, ISSN: 1619-7070, Vol: 34, Issue: 11, Page: 1843-1853
2007
- 86Citations
- 25Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations86
- Citation Indexes86
- 86
- CrossRef42
- Captures25
- Readers25
- 25
Article Description
Purpose: Monitoring HER2 expression is crucial for selection of breast cancer patients amenable to HER2-targeting therapy. The Affibody molecule Z binds to HER2 with picomolar affinity and enables specific imaging of HER2 expression. Previously, Z with the additional N-terminal mercaptoacetyl-glycyl-glycyl-glycyl (maGGG) sequence was labelled with Tc and demonstrated specific targeting of HER2-expressing xenografts. However, hepatobiliary excretion caused high radioactivity accumulation in the abdomen. We investigated whether the biodistribution of Z can be improved by substituting glycyl residues in the chelating sequence with more hydrophilic seryl residues. Methods: The Affibody molecule Z, carrying the chelators mercaptoacetyl-glycyl- seryl-glycyl (maGSG), mercaptoacetyl-glycyl-D-seryl-glycyl [maG(D-S)G] and mercaptoacetyl-seryl-seryl-seryl (maSSS), were prepared by peptide synthesis and labelled with Tc. The differences in the excretion pathways were evaluated in normal mice. The tumour targeting capacity of Tc- maSSS-Z was studied in nude mice bearing SKOV-3 xenografts and compared with the capacity of radioiodinated Z. Results: A shift towards renal excretion was obtained when glycine was substituted with serine in the chelating sequence. The radioactivity in the gastrointestinal tract was reduced threefold for the maSSS conjugate in comparison with the maGGG conjugate 4 h post injection (p.i.). The tumour uptake of Tc- maSSS-Z was 11.5±0.5% IA/g 4 h p.i., and the tumour-to-blood ratio was 76. The pharmacokinetics and uptake characteristics of technetium-labelled Z were better than those of radioiodinated Z. Conclusion: The introduction of serine residues in the chelator results in better tumour imaging properties of the Affibody molecule Z compared with glycyl-containing chelators and is favourable for imaging of tumours and metastases in the abdominal area. © 2007 Springer-Verlag.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=35348984582&origin=inward; http://dx.doi.org/10.1007/s00259-007-0474-6; http://www.ncbi.nlm.nih.gov/pubmed/17565496; http://link.springer.com/10.1007/s00259-007-0474-6; http://www.springerlink.com/index/10.1007/s00259-007-0474-6; http://www.springerlink.com/index/pdf/10.1007/s00259-007-0474-6; https://dx.doi.org/10.1007/s00259-007-0474-6; https://link.springer.com/article/10.1007/s00259-007-0474-6
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know